| Type | Public |
| HQ | Parsippany-Troy Hills, US |
| Size (employees) | 3,168 (est) |
| Website | daiichisankyo.com |
Daiichi Sankyo is headquartered in Parsippany-Troy Hills, US
Report incorrect company information
Viewing summary data as a guest
Sign up for free to see all dataKey People/Management at Daiichi Sankyo
George Nakayama
Representative Director, Chairman and CEO
Sunao Manabe
Representative Director, Member of the Board, President and COO
Toshiaki Sai
Representative Director, Member of the Board, Executive Vice President and CFO
Katsumi Fujimoto
Member of the Board, Senior Executive Officer
Noritaka Uji
Member of the Board (Outside)
Hideyuki Haruyama
Member of the Audit and Supervisory Board
Report incorrect company information
Daiichi Sankyo Office Locations
Daiichi Sankyo has an office in Parsippany-Troy Hills
Parsippany-Troy Hills, US (HQ)
2 Hilton Ct
Report incorrect company information
Daiichi Sankyo Online and Social Media Presence
253 Twitter followers
Daiichi Sankyo has 253 Twitter Followers. The number of followers has increased 1.5% month over month and increased 4.2% quarter over quarter
205 Facebook likes
Daiichi Sankyo has 205 Facebook Likes. The number of likes has decreased 0.7% month over month and increased 2.2% quarter over quarter
Report incorrect company information
Daiichi Sankyo News and Updates
October 11, 2018
Shivinder Singh offers Delhi HC to allow him to mediate with Daiichi Sankyo
The Delhi high court has directed him to come up with a ‘proposal’ to pay his share out of the arbitral award of ₹ 3,500 crore by 30 October, the next date of hearing in the Daiichi Sankyo case
September 25, 2018
Daiichi Sankyo Initiates Two Phase 3 Trials of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Positive Metastatic Breast Cancer including Head-to-Head Versus T-DM1 and Post-T-DM1 Study
TOKYO, MUNICH, and BASKING RIDGE, N.J., Sept. 25, 2018 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the first patients have been dosed in DESTINY-Breast03 and DESTINY-Breast02, two global phase 3 studies evaluating the safety and efficacy of...
September 24, 2018
Daiichi Sankyo Presents Updated Results for [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Mutated or HER2 Expressing Non-Small Cell Lung Cancer at IASLC 19th World Conference on Lung Cancer
TOKYO, MUNICH, and BASKING RIDGE, N.J., Sept. 24, 2018 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that updated phase 1 safety and efficacy data for [fam-] trastuzumab deruxtecan (DS-8201), an investigational HER2 targeting antibody drug conjugate ...
September 20, 2018
Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-8201 in Combination with KEYTRUDA® (pembrolizumab) in HER2 Expressing Breast and HER2 Expressing or HER2 Mutant Lung Cancers
TOKYO and BASKING RIDGE, N.J., Sept. 20, 2018 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that it has entered into a clinical trial collaboration agreement with a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A., known as MSD...
September 18, 2018
Daiichi Sankyo Moves NCLT To Stay Insolvency Plea Against RHC Holding
With the Daiichi-RHC matter listed for Oct. 4, the NCLT has asked RHC Holding. its lender HDFC Bank to file a reply within a week.
September 18, 2018
Daiichi Sankyo moves NCLT to stay RHC Holdings proceedings
A two-member NCLT bench has asked RHC Holdings and HDFC Bank to file a reply over Daiichi Sankyo’s move within a week
Report incorrect company information
Daiichi Sankyo Company Life and Culture
Report incorrect company information